A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Clinical trial NCT07361562 · RECRUITING

Trial details

NCT number: NCT07361562
Sponsor: Cogent Biosciences, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor, Adult ERBB2 Altered Breast Cancer ERBB2 Gene Amplification HER2 Overexpression Non-Small Cell Lung Cancer HER2

Start date: 2025-12-30
Primary completion: 2028-05-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.